Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Non-Current Deffered Revenue (2016 - 2022)

Historic Non-Current Deffered Revenue for Protalix BioTherapeutics (PLX) over the last 13 years, with Q2 2022 value amounting to $5.9 million.

  • Protalix BioTherapeutics' Non-Current Deffered Revenue rose 36453.9% to $5.9 million in Q2 2022 from the same period last year, while for Jun 2022 it was $5.9 million, marking a year-over-year increase of 36453.9%. This contributed to the annual value of $11.8 million for FY2021, which is 58706.29% up from last year.
  • Per Protalix BioTherapeutics' latest filing, its Non-Current Deffered Revenue stood at $5.9 million for Q2 2022, which was up 36453.9% from $5.9 million recorded in Q1 2022.
  • Over the past 5 years, Protalix BioTherapeutics' Non-Current Deffered Revenue peaked at $34.9 million during Q2 2019, and registered a low of $858000.0 during Q1 2021.
  • Its 5-year average for Non-Current Deffered Revenue is $15.0 million, with a median of $9.5 million in 2020.
  • As far as peak fluctuations go, Protalix BioTherapeutics' Non-Current Deffered Revenue plummeted by 9463.72% in 2020, and later soared by 58706.29% in 2021.
  • Protalix BioTherapeutics' Non-Current Deffered Revenue (Quarter) stood at $33.0 million in 2018, then crashed by 48.59% to $17.0 million in 2019, then crashed by 89.89% to $1.7 million in 2020, then soared by 587.06% to $11.8 million in 2021, then tumbled by 50.0% to $5.9 million in 2022.
  • Its last three reported values are $5.9 million in Q2 2022, $5.9 million for Q1 2022, and $11.8 million during Q4 2021.